首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

2077238

鳥氨酸轉氨甲醯酶 (OTC) 缺乏症治療市場：按藥物類型、給藥途徑、分銷管道和地區分類。

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，鳥氨酸轉氨甲醯酶 (OTC) 缺乏症治療市場價值為 9.195 億美元，預計到 2033 年將達到 12.471 億美元。預計從 2026 年到 2033 年，該市場將以 4.5% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	9.195億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.50%	2033年市場規模預測：	12.471億美元

鳥氨酸轉氨甲醯酶 (OTC) 缺乏症是一種遺傳性疾病，其特徵是血液中氨含量過高（高氨血症）。過高的氨水平會因其毒性而影響神經系統。此疾病的徵兆和症狀可能包括嗜睡、食慾不振、呼吸頻率紊亂、體溫異常、異常運動、癲癇發作或昏迷。男性和女性均可患此病。 OTC 是由 OTC 基因突變引起的，並以 X 連鎖遺傳。鳥氨酸轉氨甲醯酶缺乏症的併發症包括發育遲緩和智慧障礙。此外，還可能發生進行性肝損傷。

市場動態

預計市場參與者增加非內生性成長策略將推動預測期內市場成長。例如，2022年9月，後期生物製藥公司GENFIT宣布已達成獨家協議，收購臨床階段生物技術公司Versantis的全部股份和投票權。 Versantis致力於解決肝病領域日益成長的未滿足醫療需求。該協議將顯著擴展GENFIT的產品線，新增針對尿素循環障礙（UCD）的兒童計畫VS-01-UCD。

在鳥氨酸轉氨甲醯酶 (OTC) 缺乏症的治療方面，預計主要公司推出的新產品將推動預測期內的市場成長。例如，2022 年 9 月，製藥公司 Medunik USA 宣布推出 Pheburane 口服顆粒劑，這是一種專有的苯丁酸鈉 (NaPB) 掩味配方。 Pheburane 是一種處方藥，需搭配特定的飲食療法，用於長期治療成人和兒童的尿素循環障礙 (UCD)。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於以下參數，對全球鳥氨酸轉氨甲醯酶 (OTC) 缺乏症市場的主要公司進行了概況介紹：公司概述、產品系列、關鍵亮點、財務績效和策略。本研究涵蓋的主要公司包括：Horizon Therapeutics Plc、Bausch Health Companies Inc.、達能、雀巢、Ultragenyx Pharmaceutical、Arcturus Therapeutics, Inc.、雅培、Swedish Orphan Biovitrum AB、Acer Therapeutics Inc.、Assertio, Inc.、Assertio, Inc., EC.Sall., Inc.、Assertio, Inc.、Assertio, Inc.、Acer Therapeutics Inc.、Assertio, Inc.、Assertio, Inc.、Assertio, Inc.、Assertio, Inc.、Acer Therapeutics Inc.、Assertio Holdings, Inc.、Acer Therapeutics Inc.、Assertio, Inc.、Assertio, Inc.、Acer Therapeutics Inc.、Assertio Holdings, Inc.、Acer Therapeutics Inc.、Assert.
透過利用本報告中提出的見解，各公司的行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球鳥氨酸轉氨甲醯酶 (OTC) 缺乏症市場報告針對該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用分析全球鳥氨酸轉氨甲醯酶 (OTC) 缺乏症治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
- Horizon Therapeutics Plc
- Bausch Health Companies Inc.
- Danone
- Nestle
- Ultragenyx Pharmaceutical.
- Arcturus Therapeutics, Inc.
- Swedish Orphan Biovitrum AB
- Acer Therapeutics Inc.
- Assertio Holdings, Inc.
- iECURE
- Translate Bio, Inc.

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI5514

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is estimated to be valued at USD 919.5 Mn in 2026 and is expected to reach USD 1,247.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 919.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.50%	2033 Value Projection:	USD 1,247.1 Mn

Ornithine transcarbamylase (OTC) deficiency is a genetic disorder that causes excessive ammonia buildup in the blood (hyperammonemia). When ammonia levels are too high, it is toxic and affects the nervous system. This signs and symptoms may also include lack of energy and appetite, an uncontrollable breathing rate, body temperature, unusual body movements, seizures, or coma. This form can be found in both males and females. OTC is caused by genetic changes in the OTC gene, and it is inherited in an X-linked manner. Complications from ornithine transcarbamylase deficiency may include developmental delay and intellectual disability. Progressive liver damage may also occur.

Market Dynamics

Increasing inorganic growth strategies by market players is expected to drive the market growth over the forecast period. For instance, in September 2022, GENFIT, a late-stage biopharmaceutical company, announced it had entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, is a clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. This agreement significantly expands GENFIT's pipeline with VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD).

Increasing product launches by key players for ornithine transcarbamylase (OTC) deficiency treatment is expected to drive the market growth over the forecast period. For instance, in September 2022, Medunik USA, a pharmaceutical company, announced the launch of Pheburane oral pellets, a unique taste-masked formulation of sodium phenylbutyrate (NaPB). Pheburane is a prescription medicine, used along with a specific diet, for the long-term management of adults and children with urea cycle disorders (UCDs).

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ornithine transcarbamylase (OTC) deficiency market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Horizon Therapeutics Plc, Bausch Health Companies Inc., Danone, Nestle, Ultragenyx Pharmaceutical., Arcturus Therapeutics, Inc. , Abbott., Swedish Orphan Biovitrum AB, Acer Therapeutics Inc., Assertio Holdings, Inc., iECURE, and Translate Bio, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global ornithine transcarbamylase (OTC) deficiency market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ornithine transcarbamylase (OTC) deficiency treatment market.

Detailed Segmentation:

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)
Buphenyl
Ravicti
Ammonul
Others
Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Intravenous
Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Distribution channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Horizon Therapeutics Plc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bausch Health Companies Inc
Danone
Nestle
Ultragenyx Pharmaceutical
Arcturus Therapeutics, Inc
Abbott
Swedish Orphan Biovitrum AB
Acer Therapeutics Inc
Assertio Holdings, Inc
iECURE
Translate Bio, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Regulatory Scenario
Market Trends
Key Developments
Epidemiology
PEST Analysis
Pipeline Analysis

4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Drug Type, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Buphenyl
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Ravicti
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Ammonul
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)

5. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Route of Administration, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)

6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Distribution Channel, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)

7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Region, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033,(US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Competitive Snapshot
Heat Map Analysis
Market Share Analysis
- Horizon Therapeutics Plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Bausch Health Companies Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Danone
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Nestle
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Ultragenyx Pharmaceutical.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Arcturus Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Swedish Orphan Biovitrum AB
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Acer Therapeutics Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Assertio Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- iECURE
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Translate Bio, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies

9. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

鳥胺酸氨甲醯基轉移酶缺乏症治療市場報告：趨勢、預測和競爭分析（至2031年）

全球鳥氨酸轉氨甲醯酶缺乏症治療市場：成長、展望與競爭分析（2025-2033）

鳥氨酸轉氨甲醯酶缺乏症治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

全球鳥胺酸氨甲醯基轉移酶缺乏症市場規模：依產品類型、最終用戶、區域範圍和預測

FAQ

鳥氨酸轉氨甲醯酶 (OTC) 缺乏症治療市場：按藥物類型、給藥途徑、分銷管道和地區分類。